Skip to main content

Profiling Responders In Antibody Therapies

Objectif

"Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$. In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma. However, for most antibody therapies, only a subset of patients benefit from treatment. Thus, there is an urgent need to develop more potent therapeutic antibodies and to understand the molecular basis for the differential responses of patients to treatment.
This consortium consists of European centres of excellence being pioneers in the field of therapeutic antibody development and (pre-) clinical studies and will tackle both of these challenges:
Innovative immunocytokines L19-IL2 and F8-IL10 are developed by Philogen for the treatment of metastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.
Building on the strong background in proteomics biomarker discovery of ETH Zurich and Philochem, an innovative methodology (“HLA-peptidome analysis”) will be utilized for gaining information on the immune response in animal models and patients which receive antibody treatments. This method is based on the observation that HLA molecules in complex with peptides can be detected in the patient blood and that hundreds of HLA-associated peptides can be sequenced by mass spectrometry. The technology will be used for the profiling of responses following antibody treatment for patients with cancer and rheumatoid arthritis, as well as animal models of transplant rejection. This systems biology approach has the potential to revolutionize patient stratification in very short time.
Finally, patient selection strategies will be investigated using the clinical-grade immunocytokine (F8-IL10) as an example, monitoring antibody uptake at the site of disease by immuno-PET imaging methodologies at VUMC Amsterdam in collaboration with Philogen."

Appel à propositions

FP7-HEALTH-2012-INNOVATION-1
Voir d’autres projets de cet appel

Coordinateur

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Adresse
Raemistrasse 101
8092 Zuerich
Suisse
Type d’activité
Higher or Secondary Education Establishments
Contribution de l’UE
€ 539 987
Contact administratif
Dario Neri (Prof.)

Participants (7)

PHILOGEN SPA
Italie
Contribution de l’UE
€ 304 980
Adresse
Piazza La Lizza 7
53100 Siena
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Chiara Falciani (Dr.)
PHILOCHEM AG
Suisse
Contribution de l’UE
€ 755 028
Adresse
Wolfgang Pauli Strasse 10
8093 Zurich
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Tim Fugmann (Dr.)
STICHTING VU-VUMC
Pays-Bas
Contribution de l’UE
€ 383 034
Adresse
De Boelelaan 1105
1081 HV Amsterdam
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Gerard Hoskens (Dr.)
UNIVERSITATSKLINIKUM JENA
Allemagne
Contribution de l’UE
€ 286 260
Adresse
Kastanienstr.1
07747 Jena
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Marcus Franz (Dr.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Allemagne
Contribution de l’UE
€ 206 460
Adresse
Geschwister-scholl-platz
72074 Tuebingen
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Claus Garbe (Prof.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Contribution de l’UE
€ 285 276
Adresse
University Offices, Wellington Square
OX1 2JD Oxford
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Linda Pialek (Ms.)
MEDIZINISCHE UNIVERSITAT GRAZ
Autriche
Contribution de l’UE
€ 206 460
Adresse
Auenbruggerplatz 2
8036 Graz
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Thomas Korenjak (Mr.)